Skip to content
Neoadjuvant vs Primary Surgery: A NCDB Study with Alex Melamed episode artwork

Mar 14, 2022 39 min

Neoadjuvant vs Primary Surgery: A NCDB Study with Alex Melamed

from BMJ talk medicine Hosted by BMJ Group

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Alex Melamed to discuss neoadjuvant versus primary surgery. Alex Melamed is a gynecologist oncologist and a health services researcher at Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian Columbia Irving Medical Center. Highlights: - The emergence of evidence supporting non-inferiority of neoadjuvant chemotherapy (NACT) compared with primary surgery for advance ovarian cancer led to increased utilization of NACT. - However, while some cancer programs in the U.S. doubled their use of NACT, others continued to use this approach infrequently. - The differential adoption of NACT by cancer programs can be viewed, and analyzed, as a natural experiment using a difference-in-differences study design. - Compared with programs that continued to use NACT infrequently, high users of NACT had similar improvements in median survival, with greater reductions in 6-month and 12-month mortality.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Neoadjuvant vs Primary Surgery: A NCDB Study with Alex Melamed

0:00 39:05

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of BMJ talk medicine?

This episode is 39 minutes long.

When was this BMJ talk medicine episode published?

This episode was published on March 14, 2022.

Can I download this BMJ talk medicine episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.